TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26177651

Group type: EXPERIMENTAL
Intervention: Lifetime pesticide use (intensity-weighted) of specific pesticides
Number of subjects: 55880

Group type: EXPERIMENTAL
Intervention: More than one medical visit due to pesticide use
Number of subjects: 55880

Group type: EXPERIMENTAL
Intervention: Hospitalisation due to pesticide use
Number of subjects: 55880
Study: 26177970

Group type: EXPERIMENTAL
Intervention: AdhAQP1
Number of subjects: 11
Study: 26178412

Group type: EXPERIMENTAL
Intervention: GSK2862277 (modified dAb)
Number of subjects: 0

Group type: COMPARATOR
Intervention: GSK1995057 (parent dAb)
Number of subjects: 0
Study: 26178526

Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg/d for 3 months
Number of subjects: 28
Study: 26178723

Group type: EXPERIMENTAL
Intervention: Higher 25-hydroxyvitamin D concentrations (25(OH)D)
Number of subjects: 1683

Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D concentrations <50 nmol/L
Number of subjects: 1683

Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D concentrations
Number of subjects: 1683
Study: 26179143

Group type: EXPERIMENTAL
Intervention: Noninvasive hemoglobin measurement (SpHb; Radical-7 Pulse Co-Oximeter)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Blood gas analyzer (BGAHb; ABL 800 Flex)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Laboratory hematology analyzer (labHb; Siemens Advia)
Number of subjects: 60
Study: 26179147

Group type: EXPERIMENTAL
Intervention: Viewing personal smoking environments (PSEs)
Number of subjects: 40
Study: 26179200

Group type: EXPERIMENTAL
Intervention: Emactuzumab 900 mg, 1350 mg, or 2000 mg every 2 weeks (dose-escalation phase) and 1000 mg every 2 weeks (dose-expansion phase)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Emactuzumab
Number of subjects: 25
Study: 26180085

Group type: EXPERIMENTAL
Intervention: ASK1 inhibitor (GS-444217 delivered in chow) - early intervention (2-8 weeks after STZ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ASK1 inhibitor (GS-444217 delivered in chow) - late intervention (weeks 8-15 after STZ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (normal chow) - diabetic Nos3(-/-) mice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (normal chow) - nondiabetic Nos3(-/-) mice
Number of subjects: 0
Study: 26181029

Group type: EXPERIMENTAL
Intervention: Erlotinib monotherapy for 13 days
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Erlotinib monotherapy
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: HNSCC cells with MAPK1 E322K
Number of subjects: 1
Study: 26181034

Group type: EXPERIMENTAL
Intervention: Alpha Emitter Radium 223
Number of subjects: 0
Study: 26181354

Group type: EXPERIMENTAL
Intervention: T790M-specific EGFR inhibitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 26181891

Group type: EXPERIMENTAL
Intervention: Carfilzomib-lenalidomide-dexamethasone therapy
Number of subjects: 57
Study: 26181941

Group type: EXPERIMENTAL
Intervention: Monitoring Cerebral Autoregulation
Number of subjects: 0
Study: 26182309

Group type: EXPERIMENTAL
Intervention: Ibrutinib therapy
Number of subjects: 308
Study: 26182684

Group type: EXPERIMENTAL
Intervention: Severe reactions to tomato
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levels of IgE to rPru p3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mild tomato allergy symptoms
Number of subjects: 0
Study: 26182860

Group type: EXPERIMENTAL
Intervention: Insertable cardiac monitors (ICM)
Number of subjects: 212
Study: 26183005

Group type: EXPERIMENTAL
Intervention: Parental SG-AR level 1
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Parental SG-AR levels 4-5
Number of subjects: 359
Study: 26183044

Group type: EXPERIMENTAL
Intervention: Neoadjuvant drug therapy with oxaliplatin and capecitabine (and panitumumab for patients without KRAS, BRAF, and PIK3CA mutations)
Number of subjects: 67
Study: 26183076

Group type: EXPERIMENTAL
Intervention: Nonmyeloablative related-donor allo-BMT with post-transplantation rituximab and high-dose post-transplantation cyclophosphamide (PTCy)
Number of subjects: 83
Study: 26184520

Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 503

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 503
Study: 26184612

Group type: EXPERIMENTAL
Intervention: Self-expandable TAVR system
Number of subjects: 996
Study: 26185103

Group type: EXPERIMENTAL
Intervention: DS Titanium Ligation Clip
Number of subjects: 502
Study: 26185328

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 26185466

Group type: EXPERIMENTAL
Intervention: Extended-release morphine sulfate with sequestered naltrexone hydrochloride (MSN)
Number of subjects: 684
Study: 26185680

Group type: EXPERIMENTAL
Intervention: Session-introducing intervention with mindfulness elements
Number of subjects: 150

Group type: COMPARATOR
Intervention: Session-introducing progressive muscle relaxation
Number of subjects: 150

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 150
Study: 26185773

Group type: EXPERIMENTAL
Intervention: MOR103 0.5 mg/kg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: MOR103 1.0 mg/kg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: MOR103 2.0 mg/kg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 31
Study: 26186012

Group type: EXPERIMENTAL
Intervention: Bevacizumab (5 mg/kg every two weeks or 7.5 mg/kg every three weeks) combined with modified FOLFOX6 (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-FU 400 mg/m2 on day 1, followed by 5-FU 2400 mg/m2 intravenous infusion over 46 hours every 2 weeks)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with modified FOLFOX6
Number of subjects: 69
Study: 26186135

Group type: EXPERIMENTAL
Intervention: Urinary inorganic arsenic plus methylated species (∑As) (µg/L) during pregnancy
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Increased urinary ∑As
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Non-seroconverting women (controls)
Number of subjects: 1100
Study: 26186299

Group type: EXPERIMENTAL
Intervention: AIP mutation carriers screening
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: AIP mutation carriers with truncating AIP mutations
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: AIP mutation carriers
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Clinical screening of AIP mutation carriers
Number of subjects: 620
Study: 26186432

Group type: EXPERIMENTAL
Intervention: MDD overall group
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: MDD severity subgroups
Number of subjects: 157

Group type: COMPARATOR
Intervention: Nondepressed group
Number of subjects: 157
Study: 26186440

Group type: EXPERIMENTAL
Intervention: ART plus low doses of IL-2
Number of subjects: 12

Group type: COMPARATOR
Intervention: ART alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: IL-2 group
Number of subjects: 12

Group type: COMPARATOR
Intervention: STI group
Number of subjects: 12
Study: 26186556

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy using docetaxel, cisplatin, and fluorouracil (TPF)
Number of subjects: 40
Study: 26187031

Group type: EXPERIMENTAL
Intervention: Ledipasvir (90 mg) and sofosbuvir (400 mg) once daily for 12 weeks
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ledipasvir and sofosbuvir treatment
Number of subjects: 21
Study: 26187290

Group type: EXPERIMENTAL
Intervention: Endovascular revascularization (ER)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Bypass surgery (BS)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Femoral/profundal artery patchplasty (FAP)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Primary amputation
Number of subjects: 1200
Study: 26187300

Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa (150 μg single injection for 7 days, followed by daily recombinant FSH/hMG)
Number of subjects: 176
Study: 26187510

Group type: EXPERIMENTAL
Intervention: (90)Y-clivatuzumab tetraxetan plus low-dose gemcitabine (Arm A)
Number of subjects: 58

Group type: COMPARATOR
Intervention: (90)Y-clivatuzumab tetraxetan alone (Arm B)
Number of subjects: 58
Study: 26187603

Group type: EXPERIMENTAL
Intervention: Nonconvulsive electrotherapy (NET)
Number of subjects: 13
Study: 26187751

Group type: EXPERIMENTAL
Intervention: mFOLFOX6 (2 cycles)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: mFOLFOX6 (4 cycles)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: mFOLFOX6 (6 cycles)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Chemoradiation only (group 1)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Surgery-related complications
Number of subjects: 259
Study: 26187864

Group type: EXPERIMENTAL
Intervention: MUD transplantation with TCRαβ/CD19 depletion
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: MMRD transplantation with TCRαβ/CD19 depletion
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: MUD and MMRD transplantation with TCRαβ/CD19 depletion
Number of subjects: 37
Study: 26188212

Group type: EXPERIMENTAL
Intervention: Cholesterol efflux capacity (CEC)
Number of subjects: 101
Study: 26188235

Group type: EXPERIMENTAL
Intervention: GNAS mutation analysis in adrenal tissue
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Clinical findings in MAS
Number of subjects: 1
Study: 26189058

Group type: EXPERIMENTAL
Intervention: Tipifarnib + Radiotherapy (RT)
Number of subjects: 18
Study: 26189353

Group type: EXPERIMENTAL
Intervention: Bandage soft contact lenses (BSCLs)
Number of subjects: 19
Study: 26189885

Group type: EXPERIMENTAL
Intervention: Short sleepers (≤6 h)
Number of subjects: 11888

Group type: EXPERIMENTAL
Intervention: Long sleepers (≥9 h)
Number of subjects: 11888

Group type: EXPERIMENTAL
Intervention: Not consuming a snack or meal within 3 h before bedtime
Number of subjects: 11888

Group type: COMPARATOR
Intervention: Long sleepers
Number of subjects: 11888

Group type: EXPERIMENTAL
Intervention: AHEI-2010 score
Number of subjects: 11888
Study: 26189934

Group type: EXPERIMENTAL
Intervention: Anti-PD-1 antibodies (e.g., nivolumab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of PD-1 pathway blockade with other anticancer agents
Number of subjects: 0
Study: 26190488

Group type: EXPERIMENTAL
Intervention: VEGFR1-derived peptide vaccination in combination with gemcitabine
Number of subjects: 4

Group type: COMPARATOR
Intervention: Gemcitabine alone (implied control)
Number of subjects: 4
Study: 26190562

Group type: EXPERIMENTAL
Intervention: Allopurinol < 300 mg
Number of subjects: 1732

Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg
Number of subjects: 1732

Group type: EXPERIMENTAL
Intervention: Allopurinol > 300 mg
Number of subjects: 1732
Study: 26191050

Group type: EXPERIMENTAL
Intervention: 0.2% Chlorhexidine mouthwash application
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Essential Oils (EO) mouthwash application
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 0.2% Chlorhexidine immersion
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Essential Oils (EO) immersion
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Active mouthwash application
Number of subjects: 15

Group type: COMPARATOR
Intervention: Passive immersion
Number of subjects: 15
Study: 26193343

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 80
Study: 26193887

Group type: EXPERIMENTAL
Intervention: Adiponectin levels
Number of subjects: 120
Study: 26194453

Group type: EXPERIMENTAL
Intervention: Family Foundations (FF) intervention
Number of subjects: 259

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 259
Study: 26194541

Group type: EXPERIMENTAL
Intervention: Baked milk oral immunotherapy (BM OIT) with a dose of 1.3 g/d BM protein, increased 50% monthly under medical supervision.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Baked milk oral immunotherapy (BM OIT)
Number of subjects: 15
Study: 26194684

Group type: EXPERIMENTAL
Intervention: MLC tracking
Number of subjects: 15

Group type: COMPARATOR
Intervention: without MLC tracking
Number of subjects: 15
Study: 26194896

Group type: EXPERIMENTAL
Intervention: Posterior parasagittal in-plane ultrasound-guided infraclavicular brachial plexus block
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cadaveric dissection
Number of subjects: 18
Study: 26194996

Group type: EXPERIMENTAL
Intervention: Neural respiratory drive measured using EMGpara
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 12-month admission frequency
Number of subjects: 120
Study: 26195015

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori infection in ART-naive HIV-positive patients
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori infection in HIV-negative individuals
Number of subjects: 457
Study: 26195184

Group type: EXPERIMENTAL
Intervention: Liraglutide 0.6 mg/day for 2 weeks, followed by 1.2 mg/day, in addition to metformin
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (T2DM without NAFLD)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study: 26195220

Group type: EXPERIMENTAL
Intervention: Endothelial nitric oxide synthase-transfected endothelial progenitor cells (7 to 50 million cells, divided into 3 doses on consecutive days)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Endothelial nitric oxide synthase-transfected endothelial progenitor cells
Number of subjects: 7
Study: 26195674

Group type: EXPERIMENTAL
Intervention: Medicaid coverage (gaining Medicaid)
Number of subjects: 34849

Group type: COMPARATOR
Intervention: Not selected for Medicaid
Number of subjects: 34849
Study: 26195720

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (1.8 mg/kg) every 3 weeks for a maximum of sixteen doses
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 32
Study: 26196195

Group type: EXPERIMENTAL
Intervention: Nonacog alfa treatment
Number of subjects: 412
Study: 26196225

Group type: EXPERIMENTAL
Intervention: Ambrisentan (5 or 10 mg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ambrisentan and tadalafil (upfront initial combination therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ambrisentan
Number of subjects: 0
Study: 26196233

Group type: EXPERIMENTAL
Intervention: AMH (Antimüllerian hormone)
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Age and AMH
Number of subjects: 487
Study: 26196665

Group type: EXPERIMENTAL
Intervention: Ledipasvir and sofosbuvir for 12 weeks
Number of subjects: 335
Study: 26197243

Group type: EXPERIMENTAL
Intervention: Energy-restricted treatment (hypocaloric diet)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Baseline dietary total antioxidant capacity (TAC)
Number of subjects: 96
Study: 26197404

Group type: EXPERIMENTAL
Intervention: VAR protocol (prospective, longitudinal, multicenter study)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Echo analysis and genetic testing
Number of subjects: 60
Study: 26197982

Group type: EXPERIMENTAL
Intervention: Higher level of neighborhood social capital (informal socializing)
Number of subjects: 12568

Group type: EXPERIMENTAL
Intervention: Higher level of neighborhood social capital (voting turnout)
Number of subjects: 12568

Group type: COMPARATOR
Intervention: Individual socioeconomic position and neighborhood deprivation
Number of subjects: 12568
Study: 26198286

Group type: EXPERIMENTAL
Intervention: CI-AKI
Number of subjects: 9512
Study: 26199039

Group type: EXPERIMENTAL
Intervention: Ridaforolimus 20 mg daily (5 days/week) + MK-0752 1800 mg weekly
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ridaforolimus 30 mg daily (5 days/week) + MK-0752 1800 mg weekly
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combined ridaforolimus and MK-0752
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Maximum tolerated dose (MTD)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 28
Study: 26199392

Group type: EXPERIMENTAL
Intervention: Sequential high-dose chemotherapy (HDC) with bevacizumab preceding GemDMC (cycle 1) and ICE (cycle 2)
Number of subjects: 43
Study: 26199453

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) 40 mg every other week or monthly
Number of subjects: 846
Study: 26200040

Group type: EXPERIMENTAL
Intervention: Calcium aluminosilicate antidiarrheal (CASAD)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CASAD
Number of subjects: 10
Study: 26200236

Group type: EXPERIMENTAL
Intervention: Maternal pre-pregnancy body mass index (ppBMI)
Number of subjects: 976

Group type: EXPERIMENTAL
Intervention: Mid-pregnancy gestational weight gain (GWG)
Number of subjects: 976

Group type: EXPERIMENTAL
Intervention: Maternal pre-pregnancy body mass index (ppBMI) and mid-pregnancy GWG
Number of subjects: 976
Study: 26201019

Group type: EXPERIMENTAL
Intervention: CoroMarker (lncRNA AC100865.1)
Number of subjects: 221
Study: 26201460

Group type: EXPERIMENTAL
Intervention: Ranibizumab injections (3 injections)
Number of subjects: 1333
Study: 26201818

Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Morbidly obese patients
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nonobese patients
Number of subjects: 40

Group type: COMPARATOR
Intervention: Gallbladder emptying
Number of subjects: 40
Study: 26201817

Group type: EXPERIMENTAL
Intervention: 10 mg pyridoxine hydrochloric acid/d for 28 days
Number of subjects: 10
Study: 26202132

Group type: EXPERIMENTAL
Intervention: Serum apoE
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Serum high-density lipoprotein cholesterol
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Donor age
Number of subjects: 84
Study: 26202442

Group type: EXPERIMENTAL
Intervention: 23G vitrectomy
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: 25G vitrectomy
Number of subjects: 347

Group type: COMPARATOR
Intervention: 20G vitrectomy
Number of subjects: 347
Study: 26202647

Group type: EXPERIMENTAL
Intervention: Balance training incorporated into Pulmonary Rehabilitation (PR) three times a week
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Health care professionals (HCPs) training on balance training principles and practical application
Number of subjects: 19
Study: 26202768

Group type: EXPERIMENTAL
Intervention: Maraviroc 150 mg twice daily with a protease inhibitor
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Maraviroc 300 mg twice daily without a protease inhibitor
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Alternative regimen
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Overall maraviroc exposure
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ctrough
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Viral load close to delivery
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Children tested for HIV
Number of subjects: 18
Study: 26202922

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC)
Number of subjects: 1376

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 1376

Group type: EXPERIMENTAL
Intervention: Combination of clomiphene citrate and metformin
Number of subjects: 1376

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 1376

Group type: EXPERIMENTAL
Intervention: Current smoking status
Number of subjects: 1376
Study: 26203353

Group type: EXPERIMENTAL
Intervention: Goal-directed fluid therapy (GDFT) with arterial-based continuous stroke volume variation (SVV) monitoring
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group (standard fluid therapy)
Number of subjects: 164
Study: 26203760

Group type: EXPERIMENTAL
Intervention: Robot-assisted pterygium surgery using the DaVinci Si HD robotic Surgical System
Number of subjects: 1
Study: 26203904

Group type: EXPERIMENTAL
Intervention: Low Dietary Diversity Score (DDS)
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: Animal Source Foods (ASF) intake
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: Socio-demographic factors affecting DDS
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: Gender differences in ASF intake
Number of subjects: 886
Study: 26205215

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (GBP)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Systematic multivitamin and mineral supplementation after GBP and SG
Number of subjects: 52
Study: 26205445

Group type: EXPERIMENTAL
Intervention: Clopidogrel and subsequent prasugrel loading dose
Number of subjects: 2023

Group type: COMPARATOR
Intervention: Prasugrel loading dose alone
Number of subjects: 2023
Study: 26205955

Group type: EXPERIMENTAL
Intervention: Short-course neoadjuvant chemotherapy (NACT) followed by long-course chemoradiotherapy and definitive surgery, with a focus on the increase in circulating carbonic anhydrase IX (CAIX) levels above a threshold of 224 pg/ml after NACT.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CAIX parameter ΔNACT (change in CAIX levels post-NACT).
Number of subjects: 0
Study: 26206158

Group type: EXPERIMENTAL
Intervention: Antithrombotic management patterns (AMPs) during hospitalization and post-discharge
Number of subjects: 12922
Study: 26207061

Group type: EXPERIMENTAL
Intervention: Patient Empowerment Programme (PEP)
Number of subjects: 0
Study: 26207614

Group type: EXPERIMENTAL
Intervention: Capecitabine, oxaliplatin, and irinotecan plus bevacizumab
Number of subjects: 53
Study: 26208006

Group type: EXPERIMENTAL
Intervention: Echocardiographic screening for rheumatic heart disease (RHD) using modified WHO criteria
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: Echocardiographic screening for rheumatic heart disease (RHD) using WHF criteria
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: Echocardiographic screening for congenital heart disease
Number of subjects: 1023
Study: 26208217

Group type: COMPARATOR
Intervention: Obese mothers (n=64)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Overweight mothers (n=56)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Gestational diabetic mothers (n=79)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Normal weight controls (n=132)
Number of subjects: 331
Study: 26208483

Group type: EXPERIMENTAL
Intervention: RNA disruption assay (RDA) Zone 3
Number of subjects: 0

Group type: COMPARATOR
Intervention: RNA disruption assay (RDA) Zone 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: pCR responders in RDA Zone 3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High tumor RNA disruption
Number of subjects: 0